TLSA — Tiziana Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $137.84m
- $134.28m
Annual income statement for Tiziana Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | — | — | — | — |
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 27.4 | 14.6 | 18 | 15.8 | 21.1 |
| Operating Profit | -27.4 | -14.6 | -18 | -15.8 | -21.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.7 | -15.4 | -17.2 | -16.7 | -18.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.4 | -15.4 | -17.7 | -11.9 | -18.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.4 | -15.4 | -17.7 | -11.9 | -18.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.4 | -15.4 | -17.7 | -11.9 | -18.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.239 | -0.152 | -0.173 | -0.111 | -0.156 |